Briacell Therapeutics Corp experiences a notable surge in stock price this week.
Briacell Therapeutics Corp (BCT.TO) has seen significant movement in its stock price recently, with a 7.93% increase on Tuesday and a remarkable 22.64% rise over the past week. This uptick comes amidst the company's strategic efforts to enhance its market presence.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$41.93M
52W high
$20.40
52W low
$3.68
1W change
-4.17%
Beta
1.54
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 314.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+314.9% Upside
Current Price
C$4.82
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
61.9%
Annualized
90-Day Vol
83.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$4.03
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.54 | C$3.67 – C$5.62 |
| 60 trading days | C$4.28 | C$3.16 – C$5.79 |
| 90 trading days | C$4.03 | C$2.79 – C$5.84 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should take note of Briacell's recent stock performance and its ongoing initiatives, which may signal positive developments for the company's future prospects.
Briacell's Stock Rises 22.64% This Week
The stock's recent performance marks a stark contrast to its year-to-date decline of 43.18%, highlighting volatility and potential investor interest.
Bull case
Briacell's engagement of consulting and branding firms shows a proactive strategy for market access and commercialization. This approach could lead to future growth opportunities for the company.
Bear case
Despite the recent price increase, the stock is still significantly below its 200-day moving average. This suggests there may be underlying challenges that investors should keep in mind.
Price Action
Advertisement
Briacell Therapeutics Corp's stock closed at C$5.33 on Tuesday, reflecting a significant 7.93% increase for the day. Over the past week, the stock has surged by 22.64%, indicating a growing interest among investors.
Company News
On July 7, 2026, Briacell Therapeutics announced the engagement of consulting and branding firms aimed at supporting the commercial and market access evaluation of its product, Bria-IMT™. This strategic move is intended to enhance the company's market presence and facilitate growth.
Technical Picture
BCT.TO is currently trading above its 50-day moving average of C$4.78, representing an 11.6% increase. However, it remains significantly below its 200-day moving average of C$8.78, indicating a 39.3% decline from that benchmark. The stock's 52-week range has been between C$3.68 and C$27.20, with the current price at only 7% of that range. With a beta of 1.54, the stock exhibits higher volatility compared to the broader market.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
